Amgen Revenue Boosted By COVID-19 Manufacturing, Flat To Down Without It
Performance Highlights Need For Near-Term Growth Drivers
The company reported $6.8bn in fourth quarter revenue, missing analyst consensus of $6.9bn even with revenue from supplying Lilly’s COVID-19 antibodies. Enbrel and Aimovig fell by double digits.
